Medical therapy for peripheral arterial disease

Current Opinion in Cardiology

Volumn 27, Issue 6, 2012, Pages 592-597

  Simmons, Ashley ^a   Steffen, Kelly ^a   Sanders, Sarah ^a  

^a UNIVERSITY OF KANSAS HOSPITAL   (United States)

Author keywords

atherosclerosis; intermittent claudication; medical therapy; peripheral artery disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; GLIBENCLAMIDE; WARFARIN;

ANGIOPLASTY; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; DISEASE ASSOCIATION; HEART INFARCTION; HUMAN; KINESIOTHERAPY; LEG AMPUTATION; MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SMOKING CESSATION;

EXERCISE THERAPY; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INTERMITTENT CLAUDICATION; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PREVALENCE; RISK FACTORS; SMOKING CESSATION;

EID: 84868302792     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328357428a     Document Type: Review

References (65)

1. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 (Suppl 1):S1-S75.
2. Diehm C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation 2009; 120:2053-2061.
3. Rooke TW, Hirsch AT, Misra S, et al. ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 58:2020-2045.
4. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): Executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006; 47:1239-1312.
5. Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation 2011; 124:17-23.
6. Chen J, Mohler ER 3rd, Xie D, et al. Risk Factors for Peripheral Arterial Disease Among Patients With Chronic Kidney Disease. Am J Cardiol 2012; 110:136-141.
7. Norgren L. [New international consensus document on peripheral arterial disease. TASC II for improved care] (in Swedish). Lakartidningen 2007; 104:1474-1475.
8. Conen D, Everett BM, Kurth T, et al. Smoking, smoking cessation, [corrected] and risk for symptomatic peripheral artery disease in women: A cohort study. Ann Intern Med 2011; 154:719-726.
9. Huxley RR, WoodwardM. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: A systematic review and meta-analysis of prospective cohort studies. Lancet 2011; 378:1297-1305.
10. Kenfield SA, Stampfer MJ, Rosner BA, Colditz GA. Smoking and smoking cessation in relation to mortality in women. JAMA 2008; 299:2037-2047.
11. Cao Y, Kenfield S, Song Y, et al. Cigarette smoking cessation and total and cause-specific mortality: A 22-year follow-up study among US male physicians. Arch Intern Med 2011; 171:1956-1959.
12. Huxley RR, Yatsuya H, Lutsey PL, et al. Impact of age at smoking initiation, dosage, and time since quitting on cardiovascular disease in african americans and whites: The atherosclerosis risk in communities study. Am J Epidemiol 2012; 175:816-826.
13. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012:CD006103.
14. Brophy JM. ACP Journal Club. Review: Varenicline increases risk for serious adverse cardiovascular events in tobacco users. Ann Intern Med 2011; 155:JC4-JC5.
15. Kistler CE, Goldstein AO. The Risk of Adverse Cardiovascular Events From Varenicline Balanced Against the Benefits in Mortality From Smoking Cessation. Nicotine Tob Res 2012. [Epub ahead of print] A commentary on the risks versus benefits of varenicline in smoking cessation. 16. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustainedrelease bupropion for smoking cessation: A randomized controlled trial. JAMA 2006; 296:56-63.
16. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustainedrelease bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340:685-691.
17. West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl) 2008; 197:371-377.
18. Japuntich SJ, Zehner ME, Smith SS, et al. Smoking cessation via the internet: A randomized clinical trial of an internet intervention as adjuvant treatment in a smoking cessation intervention. Nicotine Tob Res 2006; 8 (Suppl 1):S59-S67.
19. Hennrikus D, Joseph AM, Lando HA, et al. Effectiveness of a smoking cessation program for peripheral artery disease patients: A randomized controlled trial. J Am Coll Cardiol 2010; 56:2105-2112.
20. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 (Suppl S):S5-S67.
21. Olin JW, Allie DE, Belkin M, et al. ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on performance measures, the American College of Radiology, the Society for Cardiac Angiography and Interventions, the Society for Interventional Radiology, the Society for Vascular Medicine, the Society for Vascular Nursing, and the Society for Vascular Surgery (Writing Committee to Develop Clinical Performance Measures for Peripheral Artery Disease). Circulation 2010; 122:2583-2618.
22. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
23. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: A randomized controlled trial. JAMA 2010; 303:841-848.
24. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: A metaanalysis of randomized trials. JAMA 2009; 301:1909-1919.
25. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA 2008; 300:2134-2141.
26. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337:a1840.
27. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329-1339.
28. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706-1717.
29. Writing Group Members, 2005 Writing Committee Members, ACCF/AHA Task Force Members. 2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 124:2020-2045.
30. Anand S, Yusuf S, Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357:217-227.
31. Lane DA, Lip GY. Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev 2009:CD003075.
32. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
33. Ahimastos AA, Lawler A, Reid CM, et al. Brief communication: Ramipril markedly improves walking ability in patients with peripheral arterial disease: A randomized trial. Ann Intern Med 2006; 144:660-664.
34. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A metaanalysis of randomized controlled trials. Arch Intern Med 1991; 151:1769-1776.
35. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
36. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360:7-22.
37. Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003; 108:1481-1486.
38. Aronow WS, Nayak D, Woodworth S, Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003; 92:711-712.
39. Mondillo S, Ballo P, Barbati R, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003; 114:359-364.
40. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998; 81:333-335.
41. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 2006; 47:921-929.
42. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004; 110:738-743.
43. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: The Framingham Study. J Am Geriatr Soc 1985; 33:13-18.
44. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
45. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572.
46. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
47. McDermott MM, Liu K, Greenland P, et al. Functional decline in peripheral arterial disease: Associations with the ankle brachial index and leg symptoms. JAMA 2004; 292:453-461.
48. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev 2000:CD000990.
49. Gardner AW, Skinner JS, Bryant CX, Smith LK. Stair climbing elicits a lower cardiovascular demand than walking in claudication patients. J Cardiopulm Rehabil 1995; 15:134-142.
50. Zwierska I, Walker RD, Choksy SA, et al. Upper- vs lower-limb aerobic exercise rehabilitation in patients with symptomatic peripheral arterial disease: A randomized controlled trial. J Vasc Surg 2005; 42:1122-1130.
51. Bendermacher BL, Willigendael EM, Nicolai SP, et al. Supervised exercise therapy for intermittent claudication in a community-based setting is as effective as clinic-based. J Vasc Surg 2007; 45:1192-1196.
52. Coffman JD. Intermittent claudication: Be conservative. N Engl J Med 1991; 325:577-578.
53. Radack K, Wyderski RJ. Conservative management of intermittent claudication. Ann Intern Med 1990; 113:135-146.
54. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995; 274:975-980.
55. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy versus nonsupervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev 2006:CD005263.
56. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998; 27:267-274.
57. Mora S, Cook N, Buring JE, et al. Physical activity and reduced risk of cardiovascular events: Potential mediating mechanisms. Circulation 2007; 116:2110-2118.
58. Garg PK, Tian L, Criqui MH, et al. Physical activity during daily life and mortality in patients with peripheral arterial disease. Circulation 2006; 114:242-248.
59. Pollock ML, Franklin BA, Balady GJ, et al. AHA Science Advisory. Resistance exercise in individuals with and without cardiovascular disease: Benefits, rationale, safety, and prescription: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association; Position paper endorsed by the American College of Sports Medicine. Circulation 2000; 101:828-833.
60. Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation 1994; 90:1866-1874.
61. Hirsch AT, Allison MA, Gomes AS, et al. A call to action: Women and peripheral artery disease: A scientific statement from the American Heart Association. Circulation 2012; 125:1449-1472.
62. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002; 90:1314-1319.
63. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2008:CD003748.
64. Pande RL, Hiatt WR, Zhang P, et al. A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med 2010; 15:181-188.
65. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109:523-530.